|
|
|
| home > white papers > Analysis of Biopharmaceuticals to Conform to ICHQ6B - RSSL |
|
|
 WHITE PAPERS |
|
RSSL
|
+44 (0)118 918 4024
|
|
http://www.rssl.com
|
|
University of Reading, Whiteknights Rd, Reading, West Berkshire RG6 6LA
|
|
|
Analysis of Biopharmaceuticals to Conform to ICHQ6B
|
|
Worldwide, the pharmaceuticals market is anticipated to grow from more
than USD 782 billion in 2011 to approach a value of just over USD 971
billion by the end of 2016, registering a CAGR of over 24%. In 2010 the
average medicines expenditure per person within the UK was £271, and
this is expected to increase with the ageing population. A significant
and increasing proportion of these sales are protein-based
biotherapeutics or biomolecules. Currently, these account for 19% of the
total market, and are growing at twice the rate of traditional small
molecule pharmaceuticals. It is predicted that close to 50% of the top
100 pharmaceutical products will be biomolecules by 2016. By far the
largest segment of the biopharmaceutical market is the monoclonal
antibody (MAb) with an estimated share of 25.6%, which corresponds to
USD 51.1 billion.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Countdown to the UK’s leading production line event begins
The manufacturing sector has just achieved its longest period of
expansion since 1968, boosted by global economic growth and the weakened
pound, while early signs reveal that Britain’s manufacturers are on
track to outpace the rest of the economy – setting the year on a strong
path for growth.
More info >> |
|
 |
White Papers |
 |
|
The Role of the CRO in Effective Risk-Based Monitoring
Medpace
The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >> |
|
 |
Industry Events |
 |
On Helix 2018
10-11 July 2018, The Cambridge Building, Babraham Research Campus
ON Helix is a two-day event aimed at informing delegates
of how to turn early stage inventions and ideas into innovative health treatments
(new medicines, novel biomarkers, useful medical devices or improved medical
practices).
More info >> |
|
|
|
